Boston, MA, 03/18/2014 – The anti-Cancer medicinal research is a very big area in global R&D segment and when a small cap company comes up with some kind of wonder drug it is bound to boost up its share prices. The same phenomenon can be witnessed in CEL-SCI Corporation (NYSEMKT:CVM)’s stock which has grown by almost 130% since its low of $0.53 on Dec 19, 2013. The buzz in the market is that Cel-Sci could be on the cusp of announcing some sort of a major breakthrough in cancer treatment which will radically change the cancer treatment method in the years to com.
At the core of all this is an initiative, Multikine (Leukocyte Interleukin, Injection) research, launched in late 70s by CEL-SCI Corporation (NYSEMKT:CVM)’s founder Maximilian de Clara. De Clara was of the firm view that a strong immune system plays vital role in fighting cancer. The company has also been founded around the same idea of Multikine in 1983. Multikine – now being seen as a wonder drug- attempts to strengthen the immune system before it has been compromised by radiation and chemotherapy.
After years of painstaking research CEL-SCI Corporation (NYSEMKT:CVM)’s wait for the big breakthrough may be over soon as it has initiated the Phase III of its research on this drug. This phase of trail will be aimed head and neck cancer and has already received a green signal by the US Food and Drug Administration as well as regulators in half a dozen other countries. As per the experts, in the clinical study conducted this is the largest head and neck cancer ever.
The Phase III trial – to be administered on around 880 subjects is designed to compare the current standard of care therapy (SOC) combined with Multikine investigational therapy for head and neck cancer patients vs. the SOC for these patients alone. When this trial process will be completed and FDA’s review of the entire data set on this investigational therapy, the safety and efficacy of this investigational therapy may be established beyond doubt. After FDA’s review of the entire data set on this investigational therapy, the safety and efficacy of this investigational therapy may be established beyond doubt.
As per the early-phase clinical data around two-third of head and neck cancer patients who present with advanced primary disease could be treated by this method. What adds more points to Cel Sci’s kitty is the fact that because Multikine is given before conventional cancer therapy when the immune system may be more intact, it may have a greater likelihood of activating an anti-tumor immune response.
So even though the CEL-SCI Corporation (NYSEMKT:CVM)’s scientists are keeping their fingers crossed under the strict scrutiny of USFDA, the market is relishing the prospect of a wonder drug catapulting this company from small cap segment to at least Mid-Cap. Hence the buzz and boost it is share prices.